Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CLN-978 (CD19xCD3) in Rheumatoid Arthritis. The expected timing is based on the latest available company guidance and may change.
06/06/26:- EULAR Ph1 poster showed remissions and B-cell depletion. New RA multi-dose cohort data June 10, 2026. 06/10/26:- OUTRACE RA multi-dose data showed DAS28 remission. Additional multi-dose data expected in Q3 2026. 08/06/26:- OUTRACE RA Ph1 data planned Q3 2026; Phase 2 expansion early 2027.
Verification
Confirm timing and program details against the company announcement or filing.